J&J, Pharmacyclics' ibrutinib extends lives in cancer studies
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and Pharmacyclics’ experimental drug ibrutinib helped blood cancer patients live longer, including people with high risk of recurrence, newly published study data show.